...
首页> 外文期刊>Drug discovery today >Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices: lack of harmonisation and guidelines
【24h】

Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices: lack of harmonisation and guidelines

机译:在几种生物基质中分析未结合部分的高结合蛋白抗逆转录病毒药物的挑战:缺乏统一性和指导原则

获取原文
获取原文并翻译 | 示例
           

摘要

The unbound drug concentration in plasma is usually considered the only active fraction; thus the binding of a drug to a protein limits its pharmacological actions. This is of special importance for those highly bound drugs. Therefore, binding studies can be of great utility for those drugs where relationship between free and total drug concentration is variable among patients, or it can be altered by some condition or disease, or even by interactions with other drugs. However, there is a lack of validation guidelines for the determination of unbound concentrations. Antiretroviral drugs (ARVs), protease inhibitors (PIs), efavirenz and nevirapine are highly bound to proteins. Here, we present a review on the overall methods for the study of unbound fractions of highly bound plasma protein ARVs. We also provide a critical evaluation of the methods applied, their differences and the main points to be controlled and validated.
机译:血浆中未结合的药物浓度通常被认为是唯一的活性成分。因此,药物与蛋白质的结合会限制其药理作用。这对于那些高度结合的药物特别重要。因此,结合研究对于那些患者中游离和总药物浓度之间的关系是可变的,或者由于某些状况或疾病甚至与其他药物的相互作用而改变的药物,可能具有很大的实用性。但是,缺乏确定未结合浓度的验证指南。抗逆转录病毒药物(ARV),蛋白酶抑制剂(PIs),依非韦伦和奈韦拉平与蛋白质高度结合。在这里,我们目前对研究高结合血浆蛋白ARV的未结合部分的整体方法进行综述。我们还对所应用的方法,它们的差异以及要控制和验证的要点提供了重要的评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号